Therefore, we hypothesize that the upregulation of FOXO4 activity is responsible for the greater efficacy of Tcf-4 shRNA effects in colon cancer cells compared to β-catenin shRNA. The gene discussed is FOXO4; the disease is colonic neoplasm.